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Background: Lyme disease is a tick-borne illness caused by the spirochete Borrelia   burgdorferi. 
Although antibiotic therapy is usually effective early in the disease, relapse may occur when 
administration of antibiotics is discontinued. Studies have suggested that resistance and 
  recurrence of Lyme disease might be due to formation of different morphological forms of 
B. burgdorferi, namely round bodies (cysts) and biofilm-like colonies. Better understanding 
of the effect of antibiotics on all morphological forms of B. burgdorferi is therefore crucial to 
provide effective therapy for Lyme disease.
Methods: Three morphological forms of B. burgdorferi (spirochetes, round bodies, and biofilm-
like colonies) were generated using novel culture methods. Minimum inhibitory concentration 
and minimum bactericidal concentration of five antimicrobial agents (doxycycline, amoxicillin, 
tigecycline, metronidazole, and tinidazole) against spirochetal forms of B. burgdorferi were 
evaluated using the standard published microdilution technique. The susceptibility of spiro-
chetal and round body forms to the antibiotics was then tested using fluorescent microscopy 
(BacLight™ viability staining) and dark field microscopy (direct cell counting), and these 
results were compared with the microdilution technique. Qualitative and quantitative effects 
of the antibiotics against biofilm-like colonies were assessed using fluorescent microscopy and 
dark field microscopy, respectively.
Results: Doxycycline reduced spirochetal structures ∼90% but increased the number of round 
body forms about twofold. Amoxicillin reduced spirochetal forms by ∼85%–90% and round 
body forms by ∼68%, while treatment with metronidazole led to reduction of spirochetal struc-
tures by ∼90% and round body forms by ∼80%. Tigecycline and tinidazole treatment reduced 
both spirochetal and round body forms by ∼80%–90%. When quantitative effects on biofilm-
like colonies were evaluated, the five antibiotics reduced formation of these colonies by only 
30%–55%. In terms of qualitative effects, only tinidazole reduced viable organisms by ∼90%. 
Following treatment with the other antibiotics, viable organisms were detected in 70%–85% 
of the biofilm-like colonies.
Conclusion: Antibiotics have varying effects on the different morphological forms of 
B. burgdorferi. Persistence of viable organisms in round body forms and biofilm-like colonies 
may explain treatment failure and persistent symptoms following antibiotic therapy of Lyme 
disease.
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Introduction
Lyme disease is a tickborne illness that was originally described in Old Lyme,   Connecticut, 
in 1975 and subsequently shown to be caused by the spirochete Borrelia burgdorferi.1–4 The 
disease is transmitted by tick vectors of the genus Ixodes.2–4 The life cycle and distribution Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
98
Sapi et al
of these tick vectors involves rodents, reptiles, birds, and deer.2–4 
Lyme disease sometimes begins with a skin rash called erythema 
migrans following a tick bite. The rash may be followed a few 
weeks or months later by fatigue, musculoskeletal symptoms, 
neurologic problems, and/or cardiac abnormalities.1–4
Over the last 10 years, Lyme disease has grown into a major 
public health problem in the USA and central Europe.5–7 The 
disease occurs in all age groups with equal prevalence in men 
and women.5–7 In the United States, the Centers for Disease 
Control and Prevention (CDC) reported that the number of 
Lyme disease cases has doubled during the last 15 years.5 In 
2008, a total of 3896 cases of Lyme borreliosis were reported 
in Connecticut.5 However, these figures do not reflect the 
true incidence of Lyme disease because in 2003 Connecticut 
stopped requiring mandatory laboratory reporting of the 
disease.5 Therefore, the true number of Lyme disease cases 
may be at least 10-fold higher than reported.5–7 The increasing 
trend of the disease has been ascribed to ineffective preventive 
measures, suboptimal treatment regimens, and incomplete 
understanding of the nature of the causative spirochete.
The frontline treatment for Lyme disease is administration 
of antibiotics such as doxycycline, minocycline, amoxicillin, 
cefuroxime, and ceftriaxone.8–14 Although treatment of early 
Lyme disease is generally successful, studies have shown 
that in spite of short-course antibiotic therapy of 2–4 weeks, 
some patients are not successfully treated and go on to develop 
persistent Lyme disease symptoms.8–11 Also, in the absence of 
sufficient antibiotic treatment in animals and humans, relapse of 
the disease may occur, suggesting that even after antibiotic treat-
ment, the host immune system fails to prevent recurrence.12–14 
A possible explanation for this clinical observation is the pres-
ence of different morphological forms of B. burgdorferi with 
differences in sensitivity to the antibiotic treatment.15–30
In this study, we developed novel evaluation methods 
involving optimal culture conditions for three different forms 
of B. burgdorferi (spirochetes, round bodies, and biofilm-like 
colonies) and improved bacterial viability determination 
techniques. These techniques were used to test the effective-
ness of antibiotics commonly used for Lyme disease treat-
ment against the different forms of B. burgdorferi. Our goal 
was to establish a useful in-vitro system to mimic the in-vivo 
effects of antibiotics on B. burgdorferi in order to develop 
better therapeutic approaches for Lyme disease.
Materials and methods
culturing B. burgdorferi
Low passage isolates of the B31 and S297 strains of 
B.   burgdorferi were obtained from the American Type 
  Culture Collection, Manassas, VA. B. burgdorferi was 
  cultured in Barbour-Stoner-Kelly H (BSK-H) complete 
medium, with 6% rabbit serum (Sigma, St Louis, MO, 
#B8291). The cultures were incubated at 33°C with 5% 
CO2 and maintained in sterile 15 mL glass tubes without 
  antibiotics. Homogeneous cultures having only one form 
(spirochete) of B. burgdorferi were obtained by maintain-
ing the cultures in a shaking incubator at 33°C and 250 rpm. 
At 250 rpm, there is no biofilm formation, and the culture 
remains homogeneous (E Sapi, unpublished observation).
The methods for generation and detection of round body 
forms of B. burgdorferi using culture tubes and dark field or 
fluorescent microscopy are described below. For generation of 
biofilm-like colonies of B. burgdorferi, spirochetes were inoc-
ulated in four-well chambers (BD BioCoat™ CultureSlides, 
BD Biosciences, Sparks, MD, #354557) or 24-well plates (BD 
BioCoat™ Multiwell Plates, BD Biosciences, Sparks, MD, 
#354408) coated with rat-tail collagen type I and incubated 
for 1 week without shaking. After the 1-week incubation, 
biofilm-like colonies were visualized using the qualitative 
and quantitative methods described below.
In-vitro testing of the antibacterial agents
Standard microdilution technique
To determine the minimum inhibitory concentration (MIC) 
of the antibiotics tested (the lowest concentration that will 
inhibit visible growth of B. burgdorferi spirochetes after 
a 72-hour incubation period), a standard microdilution 
method was used.31–33 For this procedure, 1 × 106 spirochetes 
were inoculated into each well of a 48-well tissue culture 
microplate containing 1 mL of BSK-H medium per well. 
The cultures were then treated with 100 µL of each antibiotic 
diluted in phosphate-buffered saline (PBS). Control cultures 
were treated with PBS alone, and all experiments were run 
in triplicate. The well plate was covered with parafilm and 
placed in the incubator for 72 hours. Cell proliferation was 
assessed using a bacterial counting chamber (Petroff-Hausser 
Counter-3902) after the 72-hour incubation.
To determine the minimum bactericidal concentration 
(MBC) of the antibiotics tested (the minimum concentra-
tion beyond which no spirochetes can be subcultured after a 
3-week incubation period), wells of a 48-well plate were filled 
with 1 mL of BSK-H medium, and 20 µL of antibiotic-treated 
spirochetes were added into each of the wells, in triplicate. 
The well plate was wrapped with parafilm and placed in the 
incubator for 3 weeks (21 days). After the incubation period, 
the plate was removed and observed for motile spirochetes 
in the culture.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Dark field microscopy and fluorescent microscopy
To further test the effect of antibiotics on spirochete and 
round body forms of B. burgdorferi, the antibiotics were 
added to a set of 2-mL polystyrene culture tubes containing 
spirochetes at a concentration of 1 × 106 cells/mL and incu-
bated at 33°C with 5% CO2. These cultures were incubated 
for various time periods (24 hours, 48 hours, 72 hours, 
and 3 weeks) and cellular growth was scored. For each of 
these timepoints, cell proliferation assays were performed 
by directly counting the different morphological forms 
of B. burgdorferi using a bacterial counting chamber and 
dark field microscopy. Also, by performing LIVE/DEAD® 
BacLight™ Bacterial Viability Assay (Molecular Probes, 
Inc, Eugene, OR), the ratio of live (green) and dead (red) 
B.   burgdorferi morphological forms was calculated by 
counting these forms using a bacterial counting chamber and 
fluorescent microscopy (see below). For the dark field and 
fluorescent microscopy experiments, a Nikon Eclipse I–series 
CF160 microscope was used (kindly donated by Dr Alan 
MacDonald and Turn the Corner Foundation).
Qualitative analysis of biofilm-like 
colonies
To qualitatively determine the effect of antibiotics on biofilm-
like colonies of B. burgdorferi, 1 × 107 cells/mL from a 
homogeneous culture of spirochetes were inoculated in a 
collagen-coated four-well plate and incubated for 1 week. 
After the 1-week incubation, biofilm-like colonies were seen 
in the wells. These biofilm-like colonies were treated with 
various concentrations of antibiotics diluted in PBS. Control 
wells were treated with PBS alone, and cultures were run in 
triplicate. Plates were incubated for 72 hours, and wells were 
fixed with 500 µL of cold alcohol-formalin-acetic acid (AFA) 
for 20   minutes. The wells were then stained with 200 µL of 
2 × BacLight™ staining mixture for 15 minutes in the dark. 
Coverslips were applied using fluorescent mounting media, and 
pictures were immediately taken of control and treated wells.
Quantitative analysis of biofilm-like 
colonies after treatment with antibiotics
To quantify B. burgdorferi biofilm-like colonies after treat-
ment with various antibiotics, collagen-coated 24-well plates 
were inoculated with 2 × 106 cells/mL from a homogeneous 
culture of B. burgdorferi. The plates were incubated for 
7 days to generate biofilm-like colonies, and then treated with 
various concentrations of antibiotics diluted in PBS or with 
PBS alone, as described above. The plates were incubated 
for 72 hours, and wells were stained with 1 mL of crystal 
violet (0.1%) for 10 minutes. After 1 mL of 95% ethanol 
was added to extract stain, the biofilm-like colonies were 
washed twice with PBS and visualized at an optical density 
of 570 nm using a BioTek spectrophotometer.
Statistical analysis
Statistical analysis was performed by two-sample paired 
t-test using NCSS statistical software (NCSS LLC, 
Kaysville, UT).
Results
To compare results from different culture techniques, MIC 
and MBC values for antibiotic treatments were calculated and 
compared with published data (Table 1). The standard pub-
lished microdilution method involves culturing B.     burgdorferi 
in microwell plates, while the new methodology made use of 
2-mL polystyrene test tubes. We observed a significant dif-
ference in MIC and MBC values between the two methods. 
Both MIC and MBC values were in agreement with published 
data when evaluated by the microdilution protocol. Using the 
novel culture tube method, MIC values increased .63-fold 
for doxycycline, .333-fold for tigecycline, .333-fold for 
amoxicillin, .833-fold for metronidazole, and .694-fold 
for tinidazole, compared with our microdilution values 
(Table 1). Furthermore, MBC values increased .8-fold 
for doxycycline, .80-fold for tigecycline, .40-fold for 
amoxicillin, .50-fold for metronidazole, and .25-fold for 
tinidazole, compared with our microdilution values (Table 1). 
Since these MIC and MBC results suggested that our novel 
method used more optimal culture conditions that allowed 
the organisms to resist antibiotic treatment, we based further 
experiments on this method.
To evaluate in-vitro antibiotic sensitivity of spiro-
chete and round body morphological forms, two strains of 
B.     burgdorferi (B31 and S297) were incubated for 72 hours 
with different antibiotics at concentrations above the calcu-
lated MIC and MBC. Antibiotic sensitivity was evaluated 
using the direct cell counting and dark field morphological 
evaluation methods (Figure 1). Treatment with these higher 
concentrations showed that doxycycline reduced spirochetal 
structures ∼90% but increased the number of cystic round 
body forms about twofold (Figure 1A). Treatment with 
metronidazole led to reduction of both spirochetal and cys-
tic round body forms by ∼70% (Figure 1B). Treatment with 
either tigecycline or   tinidazole reduced both spirochetal and 
cystic round body forms by ∼80%–90% (Figures 1C and 1D). 
Amoxicillin reduced spirochetal structures ∼70% and cystic 
round body forms by ∼68% (Figure 1E). No   difference was Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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seen in antibiotic   sensitivity testing between the two strains of 
B.   burgdorferi (B31 and S297). Using this method, we found 
that the most effective doses of the antibiotics against the spi-
rochete forms of B. burgdorferi were 250 µg/mL for doxycy-
cline, 250 µg/mL for metronidazole, 20 µg/mL for tigecycline, 
500 µg/mL for tinidazole, and 250 µg/mL for amoxicillin.
To examine in-vitro persistence of spirochete and round 
body forms of B. burgdorferi, the B31 and S297 strains were 
incubated for 72 hours and then evaluated by the direct cell 
counting and dark field evaluation methods (Figure 2). As in the 
previous set of experiments, doxycycline was found to be more 
effective against spirochetes while metronidazole and tinidazole 
were more effective against round body forms (Figure 2A). To 
test the concept that by discontinuing antibiotics, spirochete 
forms persist and cystic round body forms convert back to 
spirochete forms, the treated cultures were sub-cultured in fresh 
medium without antibiotics. After 3 weeks of subculturing, 
doxycycline had reduced spirochetal forms by ∼45% and round 
bodies by ∼85%, suggesting that round body forms converted 
back to spirochete forms in more favorable growth conditions 
(fresh growth medium and no antibiotic stress). Similarly, 
metronidazole reduced spirochetal forms by ∼50% and round 
bodies by ∼80%, while tinidazole reduced spirochetal forms 
by ∼94% and round bodies by ∼96% (Figure 2B).
To confirm preliminary results, the B31 and S297 
strains of B. burgdorferi were further evaluated in vitro for 
antibiotic sensitivity of spirochete and round body mor-
phological forms by a fluorescent microscopy technique 
(BacLight™ staining). B. burgdorferi was incubated for 
72 hours with antibiotics at concentrations higher than their 
calculated MIC and MBC. In this set of experiments, we 
calculated the post-treatment ratio of live/dead spirochetes 
and round bodies using SYTO®9 green-fluorescent nucleic 
acid stain (live cells) and propidium iodide red-fluorescent 
nucleic acid stain (dead cells) (Figure 3A). Doxycycline 
treatment reduced spirochetes by ∼94% but in the remaining 
6% of the   population, ∼5% were still alive (stained green) 
while ∼1% were dead (stained red). Tinidazole treatment 
reduced   spirochetes by ∼95%, but in the remaining 5% of 
the population ∼3% were still alive while ∼2% were dead. 
Tigecycline treatment was most effective as this reduced 
spirochetes by ∼98%, and in the remaining 2% of the 
population ∼1.5% were still alive and ∼0.5% were dead. 
Metronidazole treatment reduced spirochetes by ∼54%, 
but in the remaining 46% of the population ∼45% were 
still alive and only ∼1% were dead. Amoxicillin treatment 
reduced spirochetes by ∼69%, but in the remaining 31% of 
the population ∼30% were alive and only ∼1% cells were 
dead (Figure 3A).
Doxycycline treatment increased round bodies by ∼275% 
(Figure 3B). Out of this population ∼270% were alive and 
only ∼5% were dead. Tinidazole treatment reduced round 
bodies by ∼94%, but in the remaining 6% of the population 
only ∼2% were dead. Tigecycline treatment reduced round 
bodies by ∼96%, but in the remaining 4% of population 
only ∼1% were dead. Metronidazole treatment reduced 
round bodies by ∼68%, but in the remaining 32% of the 
population ∼15% were dead. Amoxicillin treatment reduced 
round bodies by ∼32%, but in the remaining 68% of the 
population ∼30% were dead (Figure 3B). The microscopic 
appearance of the B31 and S297 strains of B. burgdorferi 
following treatment with each antibiotic is shown in Figures 
3C and 3D, respectively.
In the next experiments, a biofilm-like form of 
B.   burgdorferi was evaluated quantitatively using a crystal 
violet staining method and qualitatively using the fluorescent 
microscopy technique (BacLight™ staining) (Figure 4). 
Using the quantitative staining method, doxycycline reduced 
biofilm-like colonies by ∼40%, tinidazole reduced biofilm-
like colonies by ∼50%–55%, tigecycline reduced biofilm-like 
colonies by ∼35%, and amoxicillin and metronidazole reduced 
biofilm-like colonies by ∼30% (Figure 4A). For qualitative 
Table 1 MIc and MBc determination by different methodsa
Antibiotics Microdilution  
method/literature 
data (MIC) µg/mL
Our data (MIC) µg/mL Microdilution  
method/literature  
data (MBC) µg/mL
Our data (MBC) µg/mL
Microdilution  
method
Direct cell  
counting
BacLight™  
staining
Microdilution  
method
Direct cell  
counting
BacLight™   
staining
Doxycycline 0.06–2.00 0.4 .25 .25 0.25–6.40 25 .200 .200
Tigecycline 0.006 0.015 .5 .5 0.05 0.125 .10 .10
Amoxicillin 0.03–2.00 0.3 .100 .100 ,0.03–32.00 5 .200 .200
Metronidazole 0.06–32.00 0.3 .250 .250 .4 10 .500 .500
Tinidazole – 0.09 .62.5 .62.5 .128 10 .250 .250
Notes: acomparison of MIc and MBc values for different antibiotics by standard microdilution method (published literature and our data) and novel direct cell counting and 
fluorescent BacLight™ staining methods in reference to spirochete forms of Borrelia burgdorferi B31.
Abbreviations: MBc, minimum bactericidal concentration; MIc, minimum inhibitory concentration.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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analysis of bacterial cells in biofilm-like colonies, cultures 
were treated as described above for 72 hours and stained 
with BacLight™ fluorescent viability stain   (Figure 4B). 
In the absence of antimicrobial agents, B. burgdorferi form 
biofilm-like colonies in which ∼98% of the colonies stain 
green (live cells) and ∼2% red (dead cells) (Figure 4Ba). 
Doxycycline-treated colonies were similar in size to control 
colonies and ∼70% stained green and ∼30% stained red 
(Figure 4Bb). Tinidazole-treated colonies were very tiny and 
loose in their morphology, and ∼10% stained green and ∼90% 
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Figure 1A Susceptibility of the spirochete and round body forms of strain B31 (top panels) and strain S297 (bottom panels) of B. burgdorferi to different concentrations 
(between calculated MIC and MBC) of five antibiotics after 72-hour treatment measured by dark-field microscopy.
Note: *P values ,0.05 indicates statistical significance compared with control.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Effect of metronidazole at different concentrations on
B. burgdorferi-B31 strain after 72 hours
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Figure 1B Susceptibility of the spirochete and round body forms of strain B31 (top panels) and strain S297 (bottom panels) of B. burgdorferi to different concentrations 
(between calculated MIC and MBC) of five antibiotics after 72-hour treatment measured by dark-field microscopy.
Note: *P values ,0.05 indicates statistical significance compared with control.
stained red (Figure 4Bc).   Tigecycline-treated colonies were 
similar in size to control colonies, and ∼70% stained green 
and ∼30% stained red (Figure 4Bd).   Metronidazole-treated 
and amoxicillin-treated colonies were larger in size than 
control colonies, and ∼80%–85% stained green while ∼20% 
stained red (Figure 4Be and 4Bf).
Discussion
The goal of our study was to demonstrate the in-vitro suscep-
tibility of different morphological forms of B. burgdorferi 
to various antibiotics using improved technical approaches 
in order to understand why antibiotic treatment for patients 
with Lyme disease could fail. To successfully eradicate Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Effect of tinidazole at different concentrations on
B. burgdorferi-B31 strain after 72 hours
P
e
r
c
e
n
t
a
g
e
 
o
f
 
c
o
n
t
r
o
l
* * *
*
* *
* * * * * *
ControlT inidazole
62.5 µg/mL
Tinidazole
250 µg/mL
Tinidazole
500 µg/mL
ControlT inidazole
62.5 µg/mL
Tinidazole
250 µg/mL
Tinidazole
500 µg/mL
20
40
60
80
100
Spirochetes
Round bodies
0
120
A
Effect of tinidazole at different concentrations on
B. burgdorferi-S297 strain after 72 hours
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Figure 1C Susceptibility of the spirochete and round body forms of strain B31 (top panels) and strain S297 (bottom panels) of B. burgdorferi to different concentrations 
(between calculated MIC and MBC) of five antibiotics after 72-hour treatment measured by dark-field microscopy. 
Note: *P values ,0.05 indicates statistical significance compared with control.
B. burgdorferi, antimicrobial agents should eliminate all 
morphological forms of the organism. Furthermore, for 
better demonstration of antibiotic susceptibility of different 
morphological forms of B. burgdorferi, there is a need for 
reliable in-vitro testing methods.
The spirochete form of B. burgdorferi is the most active 
form, with periplasmic flagella that make the organisms 
motile.15,16 Spirochetes can also enter into tissues and cause 
intracellular infection.17,18 Adverse environmental conditions 
such as change in temperature, pH, starvation, and most 
importantly antibiotic exposure can cause a phenotypic 
change in the spirochete.19,20 This change involving surface 
proteins is hypothesized to be the way in which the spirochete 
evades the host immune system.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Effect of tigecycline at different concentrations on
B. burgdorferi-S297 strain after 72 hours
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Figure 1D Susceptibility of the spirochete and round body forms of strain B31 (top panels) and strain S297 (bottom panels) of B. burgdorferi to different concentrations 
(between calculated MIC and MBC) of five antibiotics after 72-hour treatment measured by dark-field microscopy. 
Note: *P values ,0.05 indicates statistical significance compared with control.
The change in phenotypic expression could also lead to 
structural alterations in the spirochete form and induction 
of the cyst form, a knob-shaped structure containing one or 
multiple spirochetes.21–24 Cysts have a low metabolic rate 
that enables them to survive in a hostile environment until 
conditions become favorable for them to multiply again.21–25 
These cyst forms have been detected in spinal fluid, and have 
been linked to neuroborreliosis.22 The spirochetes can also dis-
integrate into minute particles called granules.25 These gran-
ules are liberated through the periplasmic sheath surrounding Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Effect of amoxicillin at different concentrations on
B. burgdorferi-B31 strain after 72 hours
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Figure 1E Susceptibility of the spirochete and round body forms of strain B31 (top panels) and strain S297 (bottom panels) of B. burgdorferi to different concentrations 
(between calculated MIC and MBC) of five antibiotics after 72-hour treatment measured by dark-field microscopy.
Note: *P values ,0.05 indicates statistical significance compared with control.
the spirochete body by budding and extrusion, and they may 
also be transmissible.25 Both cysts and granules are together 
referred to as round body forms in this study. Several studies 
have shown that B. burgdorferi can convert from the spirochete 
form to the round body form in vitro when presented with an 
unfavorable environment, and the organism can revert back to 
the spirochete form when conditions are again favorable for 
growth.21–24 The presence of atypical forms of B. burgdorferi 
may be the reason why the spirochete can survive in infected 
tissues for years or even for decades.21–24Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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Effect of tinidazole, metronidazole and doxycycline at different
concentrations on B. burgdorferi-B31 strain after 72 hours
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Figure 2A Susceptibility of the spirochete and round body forms of strain B31 (top panels) and strain S297 (bottom panels) of B. burgdorferi to the most effective 
concentrations of three antibiotics measured by dark-field microscopy. Tinidazole, metronidazole, and doxycycline effect on B. burgdorferi after 72-hour treatment. 
Note: *P values ,0.05 indicates statistical significance compared with control.
In addition to round body forms, we and others recently 
noted that B. burgdorferi has the capability to form   organized 
structures called biofilm-like colonies.26,27 Biofilms are 
adherent polysaccharide-based matrices that protect bacteria 
from the hostile host environment and facilitate persistent 
infection.28–30 These organized structures are responsible 
for a number of chronic infections, including periodontitis, 
chronic otitis media, endocarditis, gastrointestinal infection, 
and chronic lung infection. Formation of biofilm-like colonies 
would allow B. burgdorferi to survive various environmental Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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Effect of tinidazole, metronidazole and doxycycline at different
concentrations on B. burgdorferi-B31 strain after 3 weeks
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Figure 2B Susceptibility of the spirochete and round body forms of strain B31 (top panels) and strain S297 (bottom panels) of B. burgdorferi to the most effective 
concentrations of three antibiotics measured by dark-field microscopy. Tinidazole, metronidazole, and doxycycline effect on B. burgdorferi after 3 weeks of subculturing 
following 72-hour treatment. 
Note: *P values ,0.05 indicates statistical significance compared with control.
stresses including exposure to antibacterial agents.28–30 Recent 
studies suggest that bacteria live in an environment deep within 
the biofilm-like colonies where diffusion of antibiotics might be 
difficult, and in that state the bacteria could become 1000 times 
more resistant to antibiotics.28–30 This resistance could also be 
one of the reasons why conventional antibiotic therapy that 
is usually effective against free-floating bacteria becomes 
  ineffective once a pathogen forms biofilm-like colonies.28–30
In this study, novel methods of in-vitro antibiotic 
  susceptibility evaluation were used. These methods include 
optimal culture and treatment conditions such as the culture 
apparatus (tubes, to limit oxygen content), temperature, density Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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Percentage live and dead spirochetes after treatment of B31 strain with different
antibiotics at their most effective concentration after 72 hours
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Figure 3A evaluation of live/dead spirochete and round body forms of B. burgdorferi following treatment with five antibiotics measured by fluorescent microscopy using 
SYTO®9 green-fluorescent stain (live organisms) and propidium iodide red-fluorescent stain (dead organisms). Effect of doxycycline, tinidazole, tigecycline, metronidazole, 
and amoxicillin on spirochete forms of strain B31 (top panel) and strain S297 (bottom panel).
Notes: *P values calculated were ,0.05 indicating statistical significance compared with control for live and dead spirochetes.
of inoculum, amount of culture medium, and CO2 level.34,35 
These methods should counteract problems with culture vari-
ability of B. burgdorferi strains that have been described in the 
past.36,37 Furthermore our novel procedures involve better bac-
terial viability determination methods such as fluorescent and 
dark field microscopy. These microscopic evaluation methods 
are more reliable and sensitive than the standard published 
bacterial viability determination protocols.38,39 Being meta-
bolically inactive, round body forms of B. burgdorferi could 
not be detected by standard protocols, but they can be directly 
visualized under the microscope by our novel evaluation 
methods. This explains why the standard protocols measure Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Percentage live and dead round bodies after treatment of B31 strain with different
antibiotics at their most effective concentration after 72 hours
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Figure 3B evaluation of live/dead spirochete and round body forms of B. burgdorferi following treatment with five antibiotics measured by fluorescent microscopy using 
SYTO®9 green-fluorescent stain (live organisms) and propidium iodide red-fluorescent stain (dead organisms). Effect of doxycycline, tinidazole, tigecycline, metronidazole and 
amoxicillin on round body forms of strain B31 (top panel) and strain S297 (bottom panel).
Notes: *P values calculated were ,0.05 indicating statistical significance compared with control for live and dead round bodies. 
effectiveness of antibiotics only in reference to metabolically 
active spirochete forms while our novel antibiotic sensitivity 
study measures effectiveness of antibiotics in reference to all 
morphological forms of B. burgdorferi.
We found that doxycycline significantly reduced 
the spirochete form of B. burgdorferi (∼90%) but also 
increased the round body forms twofold. Amoxicillin 
reduced spirochetal forms by ∼85%–90% and round 
body forms by ∼68%. In contrast, metronidazole, tinida-
zole, and tigecycline significantly decreased both the spi-
rochete and the round body forms of B. burgdorferi, but 
live organisms could still be detected following treatment Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Ca Cb
Cc Cd
Ce Cf
Figure 3C evaluation of live/dead spirochete and round body forms of B. burgdorferi 
following treatment with five antibiotics measured by fluorescent microscopy using 
SYTO®9 green-fluorescent stain (live organisms) and propidium iodide red-fluorescent 
stain (dead organisms). Visualization of spirochete and round body forms of strain B31 
following antibiotic treatment measured by dark field microscopy: (Ca) Control; (Cb) 
Doxycycline; (cc) Tinidazole; (cd) Metronidazole; (ce) Tigecycline; (cf) Amoxicillin.
Note: All images taken at 40× magnification.
Da Db
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Figure 3D evaluation of live/dead spirochete and round body forms of B. burgdorferi 
following  treatment  with  five  antibiotics  measured  by  fluorescent  microscopy 
using  SYTO®9  green-fluorescent  stain  (live  organisms)  and  propidium  iodide 
red-fluorescent  stain  (dead  organisms).  Visualization  of  spirochete  and  round 
body forms of strain S297 following antibiotic treatment measured by dark field 
microscopy: (Da) control; (Db) Doxycycline; (Dc) Tinidazole; (Dd) Metronidazole; 
(De) Tigecycline; (Df) Amoxicillin. 
Note: All images taken at 40× magnification.
with these agents. Furthermore, the antibiotics studied 
were equally effective or ineffective against two different 
strains (B31 and S297) of B. burgdorferi. This observation 
confirms the reliability of our experimental technique. It 
remains to be seen whether combinations of antibiotics 
would be more effective than individual antibiotics alone 
in our in-vitro culture system.
Our results delineate antibiotic concentrations that are 
effective in vitro. Whether equivalent concentrations can 
be attained with clinical use of these agents in vivo remains 
to be determined.39–45 An in-vitro study showed that tige-
cycline destroyed the spirochete and round body forms of 
B.     burgdorferi.39 However, an in-vivo study in mice showed 
that tigecycline was ineffective during the late stage of Lyme 
disease based on the persistence of viable and infectious but 
nondividing or slowly dividing organisms in the animals.46 Our 
study demonstrated that tigecycline was effective against the 
spirochete and round body forms of B. burgdorferi but was not 
effective against the biofilm-like mass. One possible explana-
tion for the conflicting in-vitro and in-vivo results could be 
the presence of these biofilm-like colonies in the late stage 
of the disease, which renders B. burgdorferi more resistant 
against the antibiotic. Another possibility is that intracellular 
invasion of the spirochete in vivo could protect it from the 
action of antibiotics.17,18 Further evaluation of B. burgdorferi 
localization in tissues and biofilm-like masses is warranted.
To summarize, this study outlines novel in-vitro methods 
to determine optimal growth conditions for B. burgdorferi. The 
study also describes novel microscopic viability determination 
methods to assess three morphological forms of B. burgdorferi 
(spirochetes, round bodies, and biofilm-like colonies), and the 
methods were used to evaluate antibiotic susceptibility of the 
different morphological forms of this complex organism. Our 
in-vitro methodology will facilitate the design of experiments Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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Quantitative analysis of B31 biofilm like colonies after treatment with
antibiotics by crystal violet protocol
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Quantitative analysis of S297 biofilm like colonies after treatment with
antibiotics by crystal violet protocol
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Figure 4A Evaluation of biofilm-like colonies of B. burgdorferi. Quantitative analysis of biofilm-like colonies of strain B31 (top panel) and strain S297 (bottom panel) measured 
by crystal violet staining technique.
that mimic tissue-based in-vivo conditions in order to optimize 
the antibiotic treatment of Lyme disease.
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